ONP-002
Concussion / mild Traumatic Brain Injury (mTBI)
Phase 2Preparing Launch
Key Facts
Indication
Concussion / mild Traumatic Brain Injury (mTBI)
Phase
Phase 2
Status
Preparing Launch
Company
About Oragenics
Oragenics is a development-stage biotech focused on transforming treatment paradigms for neurological and infectious diseases through its proprietary intranasal delivery technology. Its core mission is to enable 'brain-first recovery' by bypassing the blood-brain barrier for direct CNS delivery of therapeutics. Key achievements include the completion of a Phase I safety study for its lead neurosteroid, ONP-002, for concussion, and the advancement of an intranasal COVID-19 vaccine candidate. The company's strategy leverages its platform to pursue high-need, underserved markets with non-invasive, targeted therapies.
View full company profile